+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience



Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience



World Journal of Urology 22(1): 55-59



The introduction of cisplatin-based systemic chemotherapy into the clinical routine has resulted in a substantial improvement of the recurrence-free and long-term survival of patients with metastatic testicular germ cell tumors. Late relapses after the completion of first-line therapy, comprising systemic chemotherapeutic treatment in combination with a complete resection of residual tumor masses visible in about 25-50% of patients, have been reported to occur in 1-5% of patients later than 2 years following the initial treatment. It has been reported that the risk for the development of late recurrence is correlated to the tumor burden at first diagnosis and/or the presence of teratomatous components within the primary testicular cancer. Second-line chemotherapy in combination with surgery, although not very well standardized, has been recommended as the most effective therapeutic regimen during the treatment of patients suffering from late recurrent germ cell tumors. Herein, we report our single-center experience with 14 patients in different clinical stages who developed late relapse after successful first-line therapy. In the present series, the risk for late relapse was not correlated to the clinical stage at first diagnosis or the presence of teratomatous elements within the primary tumor. It became evident that in selected cases chemotherapy alone can be considered a curative treatment option.

(PDF emailed within 0-6 h: $19.90)

Accession: 012257529

Download citation: RISBibTeXText

PMID: 15218878

DOI: 10.1007/s00345-003-0353-0


Related references

Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: A 25-year Single-center Experience. Clinical Genitourinary Cancer 15(6): E1015-E1019, 2017

Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. Journal of Clinical Oncology 13(5): 1188-1194, 1995

Active surveillance after orchiectomy for nonseminomatous testicular germ cell tumors: late relapse may occur. Urology 50(4): 588-592, 1997

Late relapse and fertility issues after testicular germ cell tumors treatment: a ten-year experience. 2007

Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis. International Urology and Nephrology 46(2): 363-369, 2014

Late relapse in stage I of nonseminomatous germ cell testicular cancer on surveillance. Bratislavske Lekarske Listy 119(1): 3-5, 2018

Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. Journal of Clinical Oncology 21(8): 1505-1512, 2003

Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. Bju International 98(2): 353-358, 2006

Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors. Medical Oncology 30(1): 494, 2013

Treatment outcome of patients with extragonadal nonseminomatous germ cell tumors: the Saitama Cancer Center experience. International Journal of Clinical Oncology 18(4): 731-734, 2014

Nonseminomatous germ celL testicular tumors. Review of the UCL experience. Acta Urologica Belgica 53(2): 394-410, 1985

Serum lactate dehydrogenase isoenzyme 1 and relapse in patients with nonseminomatous testicular germ cell tumors clinical stage I. Acta Oncologica 40(4): 536-540, 2001

Management and outcome of bilateral testicular germ cell tumors: a 25-year single center experience. International Journal of Urology 15(9): 821-826, 2008

Is retroperitoneal lymph node dissection alone optimal or sufficient therapy for clinical stage I nonseminomatous germ cell testicular tumors at high risk for relapse?. Journal of Urology 159(5 SUPPL ): 49, 1998

Five years experience with orchiectomy alone surveillance for clinical stage i nonseminomatous germ cell testicular tumors. Journal of Urology 137(4 PART 2): 211A, 1987